Clinical Trial Update: Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome [Phase 3]

View source ↗

Summary

Phase 3 cardiovascular outcomes study of alogliptin in adults with type 2 diabetes and acute coronary syndrome has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Type 2 Diabetes Mellitus

Drugs mentioned

• Nesina (alogliptin) (Alogliptin)

Snippet

Sponsor: Takeda | Conditions: Diabetes Mellitus, Type 2, Acute Coronary Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2014-04-15